No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Humans
-
Lymphoma, Follicular / drug therapy*
-
Lymphoma, Follicular / mortality*
-
Lymphoma, Follicular / pathology
-
Male
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Purines / administration & dosage*
-
Purines / adverse effects
-
Quinazolinones / administration & dosage*
-
Quinazolinones / adverse effects
-
Recurrence
-
Rituximab
-
Survival Rate
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Purines
-
Quinazolinones
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone
-
idelalisib